利鲁唑在精神病学中的应用：文献系统综述
Riluzole in psychiatry: a systematic review of the literature.
作者信息
Zarate Carlos A, Manji Husseini K
机构信息
Mark O Hatfield CRC, Bethesda, Maryland 20892, USA.
出版信息
Expert Opin Drug Metab Toxicol. 2008 Sep;4(9):1223-34. doi: 10.1517/17425255.4.9.1223.
Abstract
BACKGROUND
The glutamate system seems to be an important contributor to the pathophysiology of mood and anxiety disorders. Thus, glutamatergic modulators are reasonable candidate drugs to test in patients with mood and anxiety disorders. Riluzole, a neuroprotective agent with anticonvulsant properties approved for the treatment of amyotrophic lateral sclerosis (ALS) is one such agent.
OBJECTIVE
To assess the potential risks and benefits of riluzole treatment in psychiatric patients.
METHODS
A PubMed search was performed using the keywords 'riluzole', 'inhibitor of glutamate release' and 'glutamatergic modulator' to identify all clinical studies and case reports involving riluzole in psychiatric patients.
RESULTS/CONCLUSION: Riluzole's side effect profile is favorable and preliminary results regarding riluzole for the treatment of severe mood, anxiety and impulsive disorders are encouraging.
摘要
背景
谷氨酸系统似乎是情绪和焦虑障碍病理生理学的一个重要促成因素。因此，谷氨酸能调节剂是在情绪和焦虑障碍患者中进行测试的合理候选药物。利鲁唑是一种具有抗惊厥特性的神经保护剂，已被批准用于治疗肌萎缩侧索硬化症（ALS），它就是这样一种药物。
目的
评估利鲁唑治疗精神疾病患者的潜在风险和益处。
方法
使用关键词“利鲁唑”、“谷氨酸释放抑制剂”和“谷氨酸能调节剂”在PubMed上进行检索，以识别所有涉及利鲁唑治疗精神疾病患者的临床研究和病例报告。
结果/结论：利鲁唑的副作用较小，其用于治疗严重情绪、焦虑和冲动障碍的初步结果令人鼓舞。
相似文献
1
Riluzole in psychiatry: a systematic review of the literature.
Expert Opin Drug Metab Toxicol. 2008 Sep;4(9):1223-34. doi: 10.1517/17425255.4.9.1223.
2
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Cochrane Database Syst Rev. 2002(2):CD001447. doi: 10.1002/14651858.CD001447.
3
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Cochrane Database Syst Rev. 2007 Jan 24(1):CD001447. doi: 10.1002/14651858.CD001447.pub2.
4
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Cochrane Database Syst Rev. 2001(4):CD001447. doi: 10.1002/14651858.CD001447.
5
Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder.
Cochrane Database Syst Rev. 2021 Oct 8;10(10):CD011611. doi: 10.1002/14651858.CD011611.pub3.
6
The efficacy and safety of riluzole for neurodegenerative movement disorders: a systematic review with meta-analysis.
Drug Deliv. 2018 Nov;25(1):43-48. doi: 10.1080/10717544.2017.1413446.
7
Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease.
Cochrane Database Syst Rev. 2017 Jan 10;1(1):CD011776. doi: 10.1002/14651858.CD011776.pub2.
8
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Cochrane Database Syst Rev. 2000(2):CD001447. doi: 10.1002/14651858.CD001447.
9
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Cochrane Database Syst Rev. 2021 Sep 12;9(9):CD011612. doi: 10.1002/14651858.CD011612.pub3.
10
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.
Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.
引用本文的文献
1
Electrochemical detection of the neurotransmitter glutamate and the effect of the psychotropic drug riluzole on its oxidation response.
Anal Bioanal Chem. 2024 Mar;416(7):1707-1716. doi: 10.1007/s00216-024-05175-2. Epub 2024 Feb 16.
2
Role of the UNC13 family in human diseases: A literature review.
AIMS Neurosci. 2023 Dec 6;10(4):388-400. doi: 10.3934/Neuroscience.2023029. eCollection 2023.
3
Effects of riluzole on psychiatric disorders with anxiety or fear as primary symptoms: A systematic review.
Neuropsychopharmacol Rep. 2023 Sep;43(3):320-327. doi: 10.1002/npr2.12364. Epub 2023 Jul 18.
4
Administration of the glutamate-modulating drug, riluzole, after stress prevents its delayed effects on the amygdala in male rats.
PNAS Nexus. 2023 May 22;2(6):pgad166. doi: 10.1093/pnasnexus/pgad166. eCollection 2023 Jun.
5
Supramolecular Organization in Salts of Riluzole with Dihydroxybenzoic Acids-The Key Role of the Mutual Arrangement of OH Groups.
Pharmaceutics. 2023 Mar 8;15(3):878. doi: 10.3390/pharmaceutics15030878.
6
Riluzole, a neuroprotective agent, preserves erectile function following bilateral cavernous nerve injury in male rats.
Int J Impot Res. 2024 May;36(3):275-282. doi: 10.1038/s41443-023-00680-x. Epub 2023 Feb 14.
7
Ketamine and Other Glutamate Receptor Modulating Agents for Treatment-Resistant Depression: A Systematic Review of Randomized Controlled Trials.
Iran J Psychiatry. 2022 Jul;17(3):320-340. doi: 10.18502/ijps.v17i3.9733.
8
Structural identification of riluzole-binding site on human TRPC5.
Cell Discov. 2022 Jul 12;8(1):67. doi: 10.1038/s41421-022-00410-5.
9
Astroglial Serotonin Receptors as the Central Target of Classic Antidepressants.
Adv Neurobiol. 2021;26:317-347. doi: 10.1007/978-3-030-77375-5_13.
10
Psychosocial Crowding Stress-Induced Changes in Synaptic Transmission and Glutamate Receptor Expression in the Rat Frontal Cortex.
Biomolecules. 2021 Feb 16;11(2):294. doi: 10.3390/biom11020294.
本文引用的文献
1
Effects of glutamate-related drugs on marble-burying behavior in mice: implications for obsessive-compulsive disorder.
Eur J Pharmacol. 2008 May 31;586(1-3):164-70. doi: 10.1016/j.ejphar.2008.01.035. Epub 2008 Feb 5.
2
An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder.
J Child Adolesc Psychopharmacol. 2007 Dec;17(6):761-7. doi: 10.1089/cap.2007.0021.
3
Pharmacokinetics of riluzole: evidence for glucuronidation as a major metabolic pathway not associated with UGT1A1 genotype.
Biopharm Drug Dispos. 2008 Apr;29(3):139-44. doi: 10.1002/bdd.594.
4
Neurobiology of bipolar disorder.
Expert Rev Neurother. 2008 Jan;8(1):93-110. doi: 10.1586/14737175.8.1.93.
5
VEGF as a potential target for therapeutic intervention in depression.
Curr Opin Pharmacol. 2008 Feb;8(1):14-9. doi: 10.1016/j.coph.2007.10.013. Epub 2007 Dec 3.
6
Insulin increases retinal hemorrhage in mild oxygen-induced retinopathy in the rat: inhibition by riluzole.
Invest Ophthalmol Vis Sci. 2007 Dec;48(12):5671-6. doi: 10.1167/iovs.07-0395.
7
Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1.
Eur J Pharmacol. 2008 Jan 14;578(2-3):171-6. doi: 10.1016/j.ejphar.2007.10.023. Epub 2007 Oct 25.
8
Hippocampal N-acetylaspartate concentration and response to riluzole in generalized anxiety disorder.
Biol Psychiatry. 2008 May 1;63(9):891-8. doi: 10.1016/j.biopsych.2007.09.012. Epub 2007 Oct 29.
9
Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder.
Neuropsychopharmacology. 2008 Jan;33(1):110-33. doi: 10.1038/sj.npp.1301575. Epub 2007 Oct 3.
10
Pharmacological comparison of anticonvulsant drugs in animal models of persistent pain and anxiety.
Neuropharmacology. 2007 Oct;53(5):609-18. doi: 10.1016/j.neuropharm.2007.07.002. Epub 2007 Jul 21.
Zotero 插件